Immunogenicity is the potential or ability of a therapeutic protein to trigger an immune response when administered to patients. In today’s AI-enabled era of protein design, we have to pair “can we make it?” with “will the immune system tolerate it?”
Tyrala Consulting’s Immunogenicity Initiative tackles the questions that shape immunogenicity risk in protein-based therapeutics to help teams identify the key datasets, appropriately weigh the risks, and confidently design better therapeutics. We’re building the resources below to translate immunology and developability insights into practical design choices that allow us to harness the full potential of AI and protein design. And get us closer to the end goal: deliver innovative therapies that truly transform how we answer the question "What can biology achieve?"
